XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and contingencies (Tables)
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule Of Material Details Of Individual Settlements
Date
  
Jurisdiction
  
Settlement
Payment
*
  
Payment
Term
  
Settlement Product
  
Product WAC
Value and Term
June 7, 2019    Oklahoma    $72.3 million (paid)    1 year    N/A    N/A
December 27, 2019    Cuyahoga County, OH    $12.4 million (paid)    2.5 years   
buprenorphine naloxone
(generic Suboxone
®
)
    $15.5 million (3 years)
December 27, 2019    Summit County, OH    $7.6 million (paid)    2.5 years   
buprenorphine naloxone
(generic Suboxone
®
)
    $9.5 million (3 years)
January 18, 2022    Louisiana    $15 million    18 years   
buprenorphine naloxone
(generic Suboxone
®
)
    $3 million (1 year)
February 4, 2022    Texas    $131.5 million    15 years    naloxone hydrochloride (generic Narcan®)    $75 million (10 years)
March 21, 2022    Rhode Island    $21 million    13 years   
naloxone hydrochloride (generic Narcan
®
) and
buprenorphine naloxone (generic Suboxone
®
)
    $78.5 million (10 years)
March 30, 2022    Florida    $177.1 million    15 years    naloxone hydrochloride (generic Narcan®)    $84 million (10 years)
July 12, 2022    San Francisco    $19.5 million    13 years    naloxone hydrochloride (generic Narcan®)    $20 million (10 years)
September 19, 2022    West Virginia    $75.4 million    15 years    naloxone hydrochloride (generic Narcan®)    $27 million (10 years)
November 3, 2022    New York    $313.3 million
**
    18 years    N/A    N/A
February 24, 2023    Tribes    $108.3 million    13 years    naloxone hydrochloride (generic Narcan®)    $25 million (10 years)
 
*
 
Amounts exclude attorneys’ fees and costs, except New York.
**
 
Not including cash payment and attorneys’ fees allocated under the nationwide settlement.